effect of darolutamide in metastatic, hormone-sensitive prostate cancer
Published 2 years ago • 351 plays • Length 4:01Download video MP4
Download video MP3
Similar videos
-
6:53
perspectives on metastatic hormone-sensitive prostate cancer | bayer
-
0:51
os sensitivity analysis of darolutamide, docetaxel and adt in arasens
-
46:40
updates on management of metastatic hormone-sensitive prostate cancer
-
1:01:45
metastatic hormone sensitive prostate cancer: expert guidance for urologists
-
12:08
new fda approval: darolutamide for hormone-sensitive disease | mark scholz, md | pcri
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
0:20
darolutamide - nubeqa in a nutshell.
-
1:36
fda approves bayer's nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer
-
1:44
arasens: the addition of darolutamide to adt and docetaxel for the treatment of mhspc
-
1:40
evaluating significance of enzamet trial in metastatic hormone-sensitive prostate cancer
-
2:45
interaction of darolutamide with substrates of cyps and p-gp
-
1:52
prostate cancer: quality of life maintained with darolutamide
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
3:51
metastatic hormone-sensitive prostate cancer (mhspc)
-
1:42
darolutamide and survival in mhspc: a plain language summary of the arasens study
-
2:46
aramis: darolutamide in patients with nmcrpc
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
1:35
darolutamide and survival in nonmetastatic, castration-resistant prostate cancer